CN102973832B - 一种用于冠心病、心绞痛的药物及其制备方法 - Google Patents
一种用于冠心病、心绞痛的药物及其制备方法 Download PDFInfo
- Publication number
- CN102973832B CN102973832B CN201210566343.5A CN201210566343A CN102973832B CN 102973832 B CN102973832 B CN 102973832B CN 201210566343 A CN201210566343 A CN 201210566343A CN 102973832 B CN102973832 B CN 102973832B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- crude drug
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 241000233866 Fungi Species 0.000 claims abstract description 27
- 238000000855 fermentation Methods 0.000 claims abstract description 26
- 230000004151 fermentation Effects 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims description 40
- 210000000582 semen Anatomy 0.000 claims description 35
- 239000012530 fluid Substances 0.000 claims description 17
- 241000221377 Auricularia Species 0.000 claims description 16
- 241000121220 Tricholoma matsutake Species 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 11
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 11
- 235000011201 Ginkgo Nutrition 0.000 claims description 10
- 240000002769 Morchella esculenta Species 0.000 claims description 10
- 235000002779 Morchella esculenta Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 9
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 9
- 241000241550 Cyathula Species 0.000 claims description 8
- 241000208688 Eucommia Species 0.000 claims description 8
- 241000592346 Ginkgophyta Species 0.000 claims description 8
- 241000208966 Polygala Species 0.000 claims description 8
- 241001038563 Pseudostellaria Species 0.000 claims description 8
- 230000001186 cumulative effect Effects 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 230000009849 deactivation Effects 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 229940126532 prescription medicine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000544682 Acorus tatarinowii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 241000981179 Allium caeruleum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241000304531 Allium macrostemon Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000221454 Auriculariaceae Species 0.000 description 1
- 241000221452 Auriculariales Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000514824 Cyathula officinalis Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 241000146384 Glaux Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001636762 Polygala sibirica Species 0.000 description 1
- 241001080798 Polygala tenuifolia Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- 241000975594 Trichosanthes rosthornii Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CFKVDGBWWNMDKZ-UHFFFAOYSA-L calcium;pyridine-3-carboxylate Chemical compound [Ca+2].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 CFKVDGBWWNMDKZ-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- -1 compound saccharide Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明“一种用于冠心病、心绞痛的药物”,涉及中医药制剂,其有效成分为本发明提供的原料药的水提取物为液体培养基深层发酵药用真菌而得的发酵产物。其以中药组方药通过药用真菌共同深层发酵增加其药效,食用安全;处方全面,顾及冠心病、心绞痛、心肌梗塞等各病症状交错的患者。
Description
技术领域
本发明涉及中医药领域, 特别是一种用于冠心病、心绞痛的药物。
背景技术
冠状动脉性心脏病简称冠心病, 是由于脂质代谢异常,血液中的脂质沉着在原本光滑的动脉内膜上,在动脉内膜一些类似粥样的脂类物质堆积而成白色斑块,这些斑块渐渐增多造成动脉腔狭窄,使血流受阻,导致心脏缺血,产生心绞痛。如果动脉壁上的斑块形成溃疡或破裂,就会形成血栓,使整个血管血流完全中断,发生急性心肌梗死,甚至猝死。临床分为隐匿型、心绞痛型、心肌梗死型、心力衰竭型(缺血性心肌病)、猝死型五个类型。其中最常见的是心绞痛型,最严重的是心肌梗死和猝死两种类型。
患冠状动脉疾病的人,绝大部分是由冠状动脉粥样硬化引起的。动脉粥样硬化是一种与脂质代谢障碍,特别是与坦固醇代谢障碍有密切关系的疾病。病变早期,血液中的胆固醇及其它脂质和复合糖类在动脉内膜中沉淀下来,继而引起内膜纤维组织增生,内膜逐渐隆起、增厚,形成肉眼能够看到的灰黄色斑块;以后斑块不断扩大,中心部分因营养不足而发生软化、崩溃,可见黄色“粥样”物质;再以后动脉的中层也有脂质沉淀下来,而且中层的弹性纤维和平滑肌纤维断裂,血管内膜下逐渐发生纤维组织增生,还有钙质沉淀下来,结果,动脉管壁就变脆、变硬,管腔变窄。动脉粥样硬化,是导致心肌缺血、冠心病的最主要原因,其常发生在大型动脉,如主动脉、冠状动脉、脑动脉等重要部位的血管。
目前对于冠心病的治疗有药物治疗、手术治疗以及介入治疗。药物治疗主要用硝酸酯类,如硝酸甘油;他汀类降血脂药,如立普妥,舒降之,洛伐他丁,可延缓或阻止动脉硬化进展;抗血小板制剂,如阿司匹林每日100-300mg,终生服用;或β- 受体阻滞剂;钙通道阻滞剂等。但通常治标不治本,患者发病频率高,对药物有高度依赖作用。手术治疗主要是冠状动脉搭桥术,从患者自身其他部位取一段血管,然后将其分别接在狭窄或堵塞了的冠状动脉的两端,使血流可以通过“桥”绕道而行,从而使缺血的心肌得到氧供,而缓解心肌缺血的症状。手术治疗并不能从根本上解决引起冠心病的根本源头,并且患者承受的手术痛苦以及经济压力较大。介入治疗,具体来讲是通过大腿根部的股动脉或手腕上的桡动脉,经过血管穿刺把支架或其它器械放入冠状动脉里面,达到解除冠状动脉狭窄的目的。
在中医领域,冠心病属胸痹、心悸、真心痛范畴。多见于老年患者,临床常见心动悸、脉结代、心绞痛,疲倦乏力,胸闷气短或烦燥出汗等症候,乃本虚标实之,本虚则心气不足,心阳虚损,心脉失养,心志不宁。标实则气滞血瘀,瘨饮阻滞,故治疗本虚兼顾,以治本为要。中医治冠心病通用药物为桂枝、甘草、丹参、川芎、柴胡、太子参、茯苓、菖蒲等。
药用真菌发酵产物富含多糖,以中药提取物为液体培养基进行扩繁,其扩繁过程中能够利用中药原料药中的碳氮源转化成对人体有益的多糖,从而得到含有高纯度多糖及高纯度中药药用成分的组方药。目前未见到专门针对冠心病的效果良好的这类药物。
发明内容
本发明为冠心病患者提供一种药物,以中药组方药通过药用真菌共同深层发酵增加其药效,食用安全;处方全面,顾及冠心病、心绞痛、心肌梗塞等各病症状交错的患者。
本发明的技术方案如下:
一种用于冠心病、心绞痛的药物,其特征在于:其有效成分为以下述原料药的水提取物为液体培养基深层发酵药用真菌而得的发酵产物,
所述原料药及其重量份组份为:太子参10~20份,茯苓5~15份,石菖蒲5~15份,远志5~15份,丹参15~25份,桂枝5~10份,炙甘草3~8份,麦门冬8~12份,川芎5~15份,瓜蒌5~15份,薤白5~15份,三七5~15份,浮小麦5~15份,金铃子5~15份,大枣5~15份,决明子5~15份,川牛膝5~15份,川杜仲5~15份,银杏5~15份,天冬5~15份,生地5~15份,杏仁5~15份,石斛5~15份,
所述原料药的水提取物的质量为所述原料药的总质量的5~10倍,
所述药用真菌指黑木耳(Auricularia)液体原种、羊肚菌(Morehella esculenta (L. ) Pers)液体原种和松茸菌(Tricholoma matsutake)液体原种;三种液体原种之间的接种比例为体积比1~2:1~2:1~2。
所属药用真菌的发酵接种量为:三种液体原种的总体积与所述原料药的水提取物的体积的比例为10~15%。
所述深层发酵指在常温环境中发酵72~96小时。
所述原料药为:太子参15份,茯苓10份,石菖蒲10份,远志10份,丹参20份,桂枝8份,炙甘草5份,麦门冬10份,川芎10份,瓜蒌10份,薤白10份,三七10份,浮小麦10份,金铃子10份,大枣10份,决明子10份,川牛膝10份,川杜仲10份,银杏10份,天冬10份,生地10份,杏仁10份,石斛10份。
所述药用真菌指黑木耳(Auricularia)液体原种、羊肚菌(Morehella esculenta (L. ) Pers)液体原种、松茸菌(Tricholoma matsutake)液体原种以体积比1:1:1混合而成的混合液体原种。
所述液体原种指以1支试管斜面种扩繁成20管同规格试管斜面原种之后,再在500~625 倍试管体积的液体培养基中常温培养72~96小时得到的培养物;所述菌种液体培养基为: 0.2%磷酸氢二钾、0.2%磷酸二氢钾、0.08%硫酸锌、0.08%天冬酸、0.08%甘露醇、2%白糖、0.8%酵母浸膏、1%蛋白胨、0.3%牛肉膏、0.5%氯化钠,溶剂为水。
上述的药物的制备方法,步骤如下:
(1)制备原料药的水提取物:按重量份组份称取原料药,加入原料药重量5~10倍重量的可饮用的水煎煮1.5~2.5小时,然后过滤得提取液,再重复加水、煎煮、过滤一次,合并两次过滤所得的提取液并继续加热浓缩使提取液的总重量为原料药的5~10倍,得到原料药的水提取物;
(2)准备药用真菌液体原种:采用黑木耳、羊肚菌、松茸菌斜面种各1支,扩繁成20支同规格斜面种,扩繁所得的斜面种每支接种到25L菌种液体培养基中培养72~96小时得液体原种;
(3)水提取物置于发酵罐中并灭活,待冷却至28~34℃时,三种液体原种之间按体积比1~2:1~2:1~2同时接种到所述原料药的水提取物中,接种比例为三种液体原种总体积与所述原料药的水提取物的体积的比例为10~15%;
(4)常温深层发酵得所述药物;
所述液体原种指以1支试管斜面种扩繁成20管同规格试管斜面原种之后,再在500~625 倍试管体积的液体培养基中常温培养72~96小时得到的培养物;所述菌种液体培养基为: 0.2%磷酸氢二钾、0.2%磷酸二氢钾、0.08%硫酸锌、0.08%天冬酸、0.08%甘露醇、2%白糖、0.8%酵母浸膏、1%蛋白胨、0.3%牛肉膏、0.5%氯化钠,溶剂为水。
所述常温深层发酵得所述药物指发酵72~96小时,对发酵产物进行放罐、浓缩、焙干、过筛最后得粉状制品,装入胶囊。
所述灭活指常压下水蒸12小时。
本发明提供一种专用于冠心病患者的药物,其基于如下一个全面的处方,采用与药用真菌深层发酵的方式制备而得。该处方中,太子参益心气;茯神(茯苓)佐参调心脾;石菖蒲、远志通心窍以定志;龙骨镇静安神;桂枝、炙甘草、辛甘化阳以补心之阳;生地、麦冬养心之阴;瓜蒌、薤白去心痹阻;三七、金铃子止痛去瘀;小麦、大枣止心烦,易怒,心慌汗出;决明子、川牛膝、川杜仲防高血压性心脏病;银杏、天冬、生地、杏仁防肺源性心脏病;丹参养血,扩张血管,化瘀止痛;石斛、花粉止口渴眩晕。而通过与三种药用真菌发酵,使得处方中的药用成分更纯,药物中的植物营养成分通过发酵全部或部分地被药用真菌扩繁所利用,即被药用真菌转化为其有机组份或代谢物,如多糖类物质,使整个处方中的成分得以最大化利用并转化为有用的药用成分。以下详细说明本发明的药物的组方:
本发明中,所指的药用真菌液体原种,指母种试管1支扩至原种管20支后,在扩繁成液体原种。扩繁所用的菌种液体培养基成分为可食用成分。
黑木耳,真菌学分类属担子菌纲,木耳目,木耳科。含木耳多糖,包括L-岩藻糖,L-阿拉伯糖,D-木糖,D-甘露糖,D-葡萄糖,葡萄糖醛酸等组份。《神农本草经》载其有"益气不饥,轻身强志"之功,黑木耳又名桑耳,具有调气柔肝、养阴解毒,活血化淤之功。用于本发明的药物中,有利于解除患者体内瘀阻。 本发明采用黑木耳的原种菌丝液进行接种。
羊肚菌Morehella esculenta (L. ) Pers,又名草笠竹,是一种珍贵的食用菌和药用于食积气滞、脘腹胀满、痰壅气逆喘咳。含有异亮氨酸、亮氨酸、赖氨酸、蛋氨酸、苯丙氨酸、苏氨酸和缬氨酸等7种人体必需氨基酸。本发明采用羊肚菌原种菌丝液进行接种。
松茸菌Tricholoma matsutake,营养丰富,含有粗蛋白质17% ,粗脂肪5.8%,可溶性无氮化台物61.5 %,还含有丰富的维生素B1 、B2 、C 、尼克酸钙、磷、铁 ,益肠胃、止痛、理气化痰。无论从营养学还是治疗功能上都对冠心病患者大有裨益。本发明中采用松茸菌原种菌丝液进行接种。
太子参,又名孩儿参、童参,为石竹科多年生草本植物异叶假繁缕的块根,有补气益血、生津、补脾胃的作用。
茯苓,为寄生在松树根上的菌类植物,形状像甘薯,外皮黑褐色,里面白色或粉红色。其原生物为多孔菌科真菌茯苓的干燥菌核。
石菖蒲,Acorus tatarinowii Schott的根茎,8~9月采挖根茎,除去茎叶及细根,晒干为药用。具有开窍,化痰,健胃的功效。
远志,为远志科植物远志Polygala tenuifolia Willd.或卵叶远志Polygala sibirica L. 的干燥根。安神益智,祛痰,消肿。用于心肾不交引起的失眠多梦,健忘惊悸,神志恍惚,咳嗽痰多,疮疡肿毒,乳房肿痛。
丹参,为双子叶植物唇形科 Labiatae鼠尾草属植物丹参 Salvia miltiorrhiza Bge. 的干燥根及根茎。活血调经,祛瘀止痛,凉血消痈,清心除烦,养血安神。
桂枝,为樟科植物肉桂 Cinnamomum cassia Presl的干燥嫩枝。发汗解肌,温经通脉,助阳化气,散寒止痛。
炙甘草,为甘草的炮制加工品(取净甘草片,照蜜炙法,炒至黄色至深黄色,不粘手时取出,晾凉)。主治:脾胃虚弱,倦怠乏力,心动悸,脉结代。
麦门冬,百合科植物麦冬或沿阶草的块根,滋阴润肺;益胃生津;清心除烦。
川芎,为伞形科植物川芎的根茎,用于活血祛瘀;行气开郁;祛风止痛。
瓜蒌,葫芦科多年生草质藤本植物栝楼 Trichosanthes kirilowii Maxim. 或双边栝楼 T. rosthornii Harms 的成熟果实,清热化痰,宽胸散结,润肠通便。
薤白10份,为百合植物小根蒜、藠子、长梗薤白或天蓝小根蒜等的鳞茎。用于胸痹心痛彻背;胸脘痞闷;咳喘痰多;脘腹疼痛;泄痢后重;白带;疮疖痈肿。
三七,为五加科植物三七的根,止血药;祛瘀药。
浮小麦,浮小麦为禾本科植物小麦干瘪轻浮的颖果。夏至前后,成熟果实采收后,取瘪瘦轻浮与未脱净皮的麦粒,去灰屑,用水漂洗,晒干而得。主止阴虚发热;盗汗;自汗。
金铃子,楝科植物川楝Melia toosendan Sieb. et Zucc.的干燥成熟果实。冬季果实成熟时采收,除去杂质,干燥而得。用于胸胁、脘腹胀痛,疝痛,虫积腹痛。
大枣,大枣中的维生素P含量为所有果蔬之冠,其具有维持毛细血管通透性,改善微循环从而预防动脉硬化的作用,还可促进维生素C在人体内积蓄。大枣中所含的皂类物质,具有调节人体代谢、增强免疫力、抗炎、抗变态反应、降低血糖和胆固醇含量等作用;所含芦丁有保护毛细血管通畅、防止血管壁脆性增加。
决明子,为豆科一年生草本植物决明或小决明的干燥成熟种子,临床实验证明,喝决明子茶可以清肝明目、防止视力模糊、降血压、降血脂、减少胆固醇等,对于防治冠心病、高血压都有不错的疗效。
川牛膝,苋科植物川牛膝Cyathula officinalis Kuan 的干燥根。祛风,利湿,通经,活血。
川杜仲,杜仲科植物杜种(Eucommia ulmoides oliv)的干燥树皮,补肝肾、壮筋骨、安胎、强壮药。
银杏,为银杏科植物银杏的种子。具有敛肺定喘;止带缩尿的功能。
天冬,百合科植物天冬(天门冬)的块根,主治燥热咳嗽;阴虚劳嗽;热病伤阴;内热消渴;肠燥便秘;咽喉肿痛。
生地,玄参科多年生草本植物地黄Rehmannia glutinosa Libosch. 的新鲜或干燥的块根。具有清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、金疮瘀、凉血、止血的功效。
杏仁,本品主入肺经。味苦能降,且兼疏利开通之性。临床报道,大杏仁可以明显降低高血脂患者的血脂水平,Spiller(1990年)认为杏仁中的单不饱和脂肪酸有助于降低患者轻度升高的血脂,且无需严格限制饮食。
石斛,Herba Dendrobii的茎,益胃生津,滋阴清热。
本发明中采用的这些原料药均可自普通中药房中购买到。
本发明还进一步提供了该药物的制备方法。
本发明提供的药物的剂型没有限制,为了方便保存以及口感舒适,优选炼蜜成丸。
本发明还请求保护该药物作为制备治疗冠心病的制药原料的权利。
具体实施方式
以下通过具体实施方式说明本发明。
材料准备:
黑木耳(Auricularia)母种,购自中国农业微生物菌种保藏管理中心(Agricultural Culture Collection of China 英文缩写ACCC),保藏编号50438),规格:试管斜面种(试管规格18mm×180mm,约40毫升),联系方式010-68918636 010-68918651 010-68918683 accccaas.ac.cn。
羊肚菌(Morehellaspp esculenta (L. ) Pers)母种,中国农业微生物菌种保藏管理中心(Agricultural Culture Collection of China 英文缩写ACCC),保藏编号51837。规格:试管斜面种(试管规格18mm×180mm,约40毫升),联系方式010-68918636 010-68918651 010-68918683 accccaas.ac.cn。
松茸菌(Tricholoma matsutake)母种,购自中国农业微生物菌种保藏管理中心 保藏编号51588. 规格:试管斜面种(试管规格18mm×180mm,约40毫升),联系方式010-68918636 010-68918651 010-68918683 accccaas.ac.cn。
用于接种的真菌液体原种的制备方法如下:
斜面种—扩繁斜面种-扩繁液体原种:试管斜面母种,1管斜面种扩繁成20管同规格斜面原种,其中斜面培养基为马铃薯葡萄糖琼脂培养基(质量体积比:马铃薯30%、葡萄糖2%、琼脂2%,溶剂为水);每管斜面原种采用以下菌种液体培养基扩繁成50瓶500cm液体原种菌丝液。
菌种液体培养基(其组份为质量体积比): 0.2%磷酸氢二钾、0.2%磷酸二氢钾、0.08%硫酸锌、0.08%天冬酸、0.08%甘露醇、2%白糖、0.8%酵母浸膏、1%蛋白胨、0.3%牛肉膏、0.5%氯化钠,溶剂为水。
扩繁条件为:将斜面试管原种分为50份,每份接种到盛有500毫升菌种液体培养基的玻璃瓶中,于常温,20次/min振荡培养72小时得到真菌液体原种。
实施例1.本发明的药物的制备
原料药配方:太子参20份,茯苓12份,石菖蒲13份,远志5份,丹参18份,桂枝5份,炙甘草6份,麦门冬11份,川芎12份,瓜蒌5份,薤白11份,三七5份,浮小麦7份,金铃子15份,大枣5份,决明子11份,川牛膝8份,川杜仲15份,银杏5份,天冬15份,生地12份,杏仁9份,石斛8份。
步骤1.制备原料药的水提取物:按重量份组份称取原料药 共10kg,加入原料药重量8倍重量的可饮用水即80kg煎煮1.5~2.5小时,然后过滤得提取液,再重复加水、煎煮、过滤一次,合并两次过滤所得的提取液并继续加热浓缩,使提取液的总重量为80kg,得到原料药的水提取物。
步骤2.原料药的水提取物灌装到发酵罐中,并将发酵罐推入《饱和蒸气无压锅炉》专利号为ZL200320126611.8的锅炉中常压水蒸汽灭活12小时。
步骤3.接种,待发酵罐内底物冷却至28~34℃时,用名称为“食用菌液体注射杆及包含该注射杆的注射器”专利号为ZL200320126960.X的接种注射器接种以下三种真菌液体原种:黑木耳(Auricularia)、羊肚菌(Morehella esculenta (L. ) Pers)、松茸菌(Tricholoma matsutake)液体原种,三种液体原种按2:1:1的比例同时接种,接种时三种液体原种的总体积与原料药的水提取物的体积比为10%。
步骤4.深层发酵:常温发酵144小时,放罐后得到的深层发酵产物,进行浓缩,焙干,过筛得粉状制品,装入胶囊。制成的胶囊每粒所含有的粉状制品相当于30g原料药。
实施例2.本发明的药物的制备
原料药配方:太子参15份,茯苓10份,石菖蒲10份,远志10份,丹参20份,桂枝8份,炙甘草5份,麦门冬10份,川芎10份,瓜蒌10份,薤白10份,三七10份,浮小麦10份,金铃子10份,大枣10份,决明子10份,川牛膝10份,川杜仲10份,银杏10份,天冬10份,生地10份,杏仁10份,石斛10份。
制备步骤同实施例1.只是,步骤3接种过程中,三种原种按1:1:1的比例同时接种。接种时三种液体原种的总体积与原料药的水提取物的体积比为15%,常温发酵96小时。
实施例3.本发明的药物的制备
原料药配方:太子参10份,茯苓5份,石菖蒲15份,远志9份,丹参25份,桂枝10份,炙甘草8份,麦门冬8份,川芎15份,瓜蒌9份,薤白15份,三七12份,浮小麦15份,金铃子5份,大枣15份,决明子15份,川牛膝5份,川杜仲9份,银杏11份,天冬10份,生地5份,杏仁15份,石斛5份;
制备步骤同实施例1.只是,步骤3接种过程中,三种原种按2:2:1的比例同时接种。接种时三种液体原种的总体积与原料药的水提取物的体积比为15%常温发酵时间120时间。
实施例4.本发明的药物的制备
原料药配方:太子参12份,茯苓15份,石菖蒲5份,远志15份,丹参15份,桂枝7份,炙甘草3份,麦门冬12份,川芎5份,瓜蒌15份,薤白5份,三七15份,浮小麦5份,金铃子13份,大枣13份,决明子5份,川牛膝15份,川杜仲5份,银杏15份,天冬5份,生地15份,杏仁5份,石斛15份。
制备步骤同实施例1.只是,步骤3接种过程中,三种原种按2:1:2的比例同时接种。接种时三种液体原种的总质量与原料药的水提取物的体积比为10%,发酵76小时。
服用方案: 实施例1~4的药物,每天服用3次,每次3粒,一天共9粒。随三餐服用。
临床典型病例:
一、 郑新鼎:男,88岁,福建福州人,香港居民,胸外科主任医师,院长,福建省人大代表,联系电话13959393668(其子电话),心梗面积达75%,连续实施例2所制的药物四年,免服西药,临床症状见好转,可独自一人去图书馆,已推迟为其做搭架手术,于今年五月高龄去世。
二、 邓先妹:女,51岁,广东省高要市河台镇河边崀村委会船尾组人,联系电话13189232562,曾在两个月零十五天内因心肌梗塞送医院抢救两次,服药(实施例1)后半年均平安,至今正常生活,做轻微家务。
三、 其余5名临床病例,先后服用实施例3, 4所制备的药物,其临床症状都得以改善,服药期间及其后半年内无发作。
Claims (9)
1.一种用于冠心病、心绞痛的药物,其特征在于:其有效成分为以下述原料药的水提取物为液体培养基深层发酵药用真菌而得的发酵产物;
所述原料药及其重量份组份为:太子参10~20份,茯苓5~15份,石菖蒲5~15份,远志5~15份,丹参15~25份,桂枝5~10份,炙甘草3~8份,麦门冬8~12份,川芎5~15份,瓜蒌5~15份,薤白5~15份,三七5~15份,浮小麦5~15份,金铃子5~15份,大枣5~15份,决明子5~15份,川牛膝5~15份,川杜仲5~15份,银杏5~15份,天冬5~15份,生地5~15份,杏仁5~15份,石斛5~15份,
所述原料药的水提取物的质量为所述原料药的总质量的5~10倍,
所述药用真菌包括黑木耳(Auricularia)液体原种、羊肚菌(Morehella esculenta (L. ) Pers)液体原种和松茸菌(Tricholoma matsutake)液体原种;三种液体原种之间的接种比例为体积比1~2:1~2:1~2。
2.根据权利要求1所述的药物,所属药用真菌的发酵接种量为:三种液体原种的总体积与所述原料药的水提取物的体积的比例为10~15%。
3.根据权利要求1所述的药物,所述深层发酵指在常温环境中发酵72~96小时。
4.根据权利要求1所述的药物,所述原料药为:太子参15份,茯苓10份,石菖蒲10份,远志10份,丹参20份,桂枝8份,灸甘草5份,麦门冬10份,川芎10份,瓜蒌10份,薤白10份,三七10份,浮小麦10份,金铃子10份,大枣10份,决明子10份,川牛膝10份,川杜仲10份,银杏10份,天冬10份,生地10份,杏仁10份,石斛10份。
5.根据权利要求1~4任一所述的药物,三种液体原种之间的接种比例为体积比1:1:1。
6.根据权利要求5所述的药物,所述液体原种指以1支试管斜面母种扩繁成20管同规格试管斜面原种之后,每管试管斜面种接种到25L菌种液体培养基中培养72~96小时得的培养物;所述菌种液体培养基为: 0.2%磷酸氢二钾、0.2%磷酸二氢钾、0.08%硫酸锌、0.08%天冬酸、0.08%甘露醇、2%白糖、0.8%酵母浸膏、1%蛋白胨、0.3%牛肉膏、0.5%氯化钠,溶剂为水。
7.权利要求1~6任一所述的药物的制备方法,步骤如下:
(1)制备原料药的水提取物:按重量份组份称取原料药,加入原料药重量5~10倍重量的可饮用的水煎煮1.5~2.5小时,然后过滤得提取液,再重复加水、煎煮、过滤一次,合并两次过滤所得的提取液并继续加热浓缩使提取液的总重量为原料药的5~10倍,得到原料药的水提取物;
(2)准备药用真菌液体原种:采用黑木耳、羊肚菌、松茸菌试管斜面母种各1支,分别扩繁成20支同规格试管斜面种,每管试管斜面种接种到25L菌种液体培养基中培养72~96小时得液体原种;
(3)水提取物置于发酵罐中并灭活,待冷却至28~34℃时,三种液体原种之间按体积比1~2:1~2:1~2同时接种到所述原料药的水提取物中,接种比例为三种液体原种总体积与所述原料药的水提取物的体积的比例为10~15%;
(4)常温深层发酵得所述药物;
所述菌种液体培养基为: 0.2%磷酸氢二钾、0.2%磷酸二氢钾、0.08%硫酸锌、0.08%天冬酸、0.08%甘露醇、2%白糖、0.8%酵母浸膏、1%蛋白胨、0.3%牛肉膏、0.5%氯化钠,溶剂为水。
8.根据权利要求7所述的制备方法,所述常温深层发酵得所述药物指发酵72~96小时,对发酵产物进行放罐、浓缩、焙干、过筛最后得粉状制品,装入胶囊。
9.根据权利要求7所述的制备方法, 所述灭活指常压下水蒸12小时。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210566343.5A CN102973832B (zh) | 2012-12-24 | 2012-12-24 | 一种用于冠心病、心绞痛的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210566343.5A CN102973832B (zh) | 2012-12-24 | 2012-12-24 | 一种用于冠心病、心绞痛的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102973832A CN102973832A (zh) | 2013-03-20 |
| CN102973832B true CN102973832B (zh) | 2014-11-05 |
Family
ID=47848367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210566343.5A Active CN102973832B (zh) | 2012-12-24 | 2012-12-24 | 一种用于冠心病、心绞痛的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102973832B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
| CN101904919A (zh) * | 2010-07-09 | 2010-12-08 | 彭都 | 一种治疗痔疮的药物及其制备方法 |
-
2012
- 2012-12-24 CN CN201210566343.5A patent/CN102973832B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (zh) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | 一种通心络药物组合物及应用 |
| CN101904919A (zh) * | 2010-07-09 | 2010-12-08 | 彭都 | 一种治疗痔疮的药物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 李斯炽心痛治验;王忆卓等;《中国社区医师》;20101015(第38期);全文 * |
| 王忆卓等.李斯炽心痛治验.《中国社区医师》.2010,(第38期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102973832A (zh) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101695376B (zh) | 预防糖尿病的保健食品 | |
| CN102178840B (zh) | 用于阴虚体质人缓解津液不足症状的中药制剂及其制备方法和应用 | |
| CN103740558A (zh) | 一种石斛酒及其制备方法 | |
| CN105166235A (zh) | 一种气血双补降三高的保健茶及其制备方法 | |
| CN103520621B (zh) | 一种治疗老年性白内障的中药组合物及其制备方法 | |
| CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
| CN102309615B (zh) | 金钱龟参茸酒 | |
| CN101095768A (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
| CN103463464B (zh) | 一种对糖尿病具有治疗作用的保健药酒 | |
| CN103182008A (zh) | 一种稳压及降压中药制作方法 | |
| CN103495115B (zh) | 一种对糖尿病具有治疗作用的药酒 | |
| CN102973832B (zh) | 一种用于冠心病、心绞痛的药物及其制备方法 | |
| CN107320631A (zh) | 一种抗疲劳中药组合物及其制备方法 | |
| CN102579818A (zh) | 一种藏药组合物及其制备方法与应用 | |
| CN102343049A (zh) | 一种治疗肝阳上亢型高血压病的中药胶囊 | |
| CN1279949C (zh) | 一种轻身益寿中药 | |
| CN105343675A (zh) | 一种治疗肥胖症的中药制剂及其制备方法 | |
| CN104606570A (zh) | 一种适宜糖尿病患者服用的消渴代茶饮及制备方法 | |
| CN104547999A (zh) | 产后发汗用油 | |
| CN106266427A (zh) | 一种治疗肾病的中药药酒及其制备方法 | |
| CN105412824A (zh) | 一种治疗肥胖症的药物组合物 | |
| CN104606462A (zh) | 调理酒精性脂肪肝的药剂及制备 | |
| CN104223062A (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
| CN101095775A (zh) | 治疗糖尿病性耳聋的一种中药 | |
| CN109395037A (zh) | 一种治疗脑痴呆的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 435503 Changqing East Road, Longgan Lake Management area, Huanggang, Hubei Province, No. 31 Patentee after: Hubei Huizhong pharmaceutical Limited by Share Ltd Address before: 435503 Changqing Road, Longgan Lake Management area, Huanggang, Hubei Province, No. 31 Patentee before: Hubei Huizhong Pharmaceutical Co., Ltd. |